Cullinan Associates’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-6,320
| Closed | -$282K | – | 226 |
|
|
2021
Q1 | $282K | Buy |
6,320
+160
| +3% | +$7.26K | 0.02% | 189 |
|
|
2020
Q4 | $283K | Buy |
6,160
+80
| +1% | +$3.67K | 0.02% | 173 |
|
|
2020
Q3 | $286K | Buy |
6,080
+240
| +4% | +$12K | 0.02% | 161 |
|
|
2020
Q2 | $298K | Sell |
5,840
-640
| -10% | -$32.8K | 0.02% | 160 |
|
|
2020
Q1 | $307K | Sell |
6,480
-15,200
| -70% | -$811K | 0.03% | 149 |
|
|
2019
Q4 | $1.27M | Sell |
21,680
-720
| -3% | -$40K | 0.09% | 120 |
|
|
2019
Q3 | $1.2M | Buy |
22,400
+640
| +3% | +$32.9K | 0.09% | 122 |
|
|
2019
Q2 | $1.09M | Sell |
21,760
-1,600
| -7% | -$80.3K | 0.08% | 128 |
|
|
2019
Q1 | $1.22M | Sell |
23,360
-240
| -1% | -$12K | 0.09% | 126 |
|
|
2018
Q4 | $1.13M | Buy |
23,600
+5,040
| +27% | +$248K | 0.09% | 120 |
|
|
2018
Q3 | $932K | Sell |
18,560
-720
| -4% | -$36.6K | 0.07% | 132 |
|
|
2018
Q2 | $971K | Sell |
19,280
-1,680
| -8% | -$84.6K | 0.07% | 129 |
|
|
2018
Q1 | $1.02M | Sell |
20,960
-80
| -0.4% | -$3.73K | 0.08% | 127 |
|
|
2017
Q4 | $933K | Buy |
21,040
+8,960
| +74% | +$414K | 0.07% | 134 |
|
|
2017
Q3 | $613K | Buy |
12,080
+1,359
| +13% | +$68.9K | 0.05% | 152 |
|
|
2017
Q2 | $578K | Buy |
10,721
+800
| +8% | +$42.6K | 0.05% | 158 |
|
|
2017
Q1 | $523K | Sell |
9,921
-3,872
| -28% | -$196K | 0.04% | 165 |
|
|
2016
Q4 | $664K | Buy |
13,793
+376
| +3% | +$18.6K | 0.06% | 155 |
|
|
2016
Q3 | $723K | Buy |
13,417
+1,200
| +10% | +$65.8K | 0.06% | 149 |
|
|
2016
Q2 | $662K | Buy |
12,217
+3,760
| +44% | +$198K | 0.05% | 148 |
|
|
2016
Q1 | $429K | Buy |
8,457
+480
| +6% | +$23.9K | 0.04% | 162 |
|
|
2015
Q4 | $402K | Sell |
7,977
-800
| -9% | -$40.8K | 0.04% | 167 |
|
|
2015
Q3 | $422K | Buy |
8,777
+560
| +7% | +$29.2K | 0.04% | 180 |
|
|
2015
Q2 | $428K | Sell |
8,217
-160
| -2% | -$9.01K | 0.04% | 179 |
|
|
2015
Q1 | $483K | Buy |
+8,377
| New | +$480K | 0.04% | 178 |
|
|
2014
Q4 | – | Sell |
-27,097
| Closed | -$1.56M | – | 90 |
|
|
2014
Q3 | $1.56M | Buy |
+27,097
| New | +$1.66M | 0.18% | 69 |
|
|
2014
Q2 | – | Sell |
-30,537
| Closed | -$2.04M | – | 88 |
|
|
2014
Q1 | $2.04M | Buy |
30,537
+11,600
| +61% | +$784K | 0.23% | 56 |
|
|
2013
Q4 | $1.26M | Buy |
18,937
+7,280
| +62% | +$472K | 0.15% | 65 |
|
|
2013
Q3 | $731K | Buy |
+11,657
| New | +$750K | 0.1% | 78 |
|
Other funds holding GSK
BCIM
Cullinan Associates's GSK Position: Q2 2021 in Review
Cullinan Associates sold out of GSK (GSK) in Q2 2021, closing a stake of 6,320 shares — an estimated $282K sold.
Cullinan Associates first reported a position in GSK in Q3 2013 and held it in 29 quarters. The position peaked at $2.04M in Q1 2014. 798 funds tracked by Wall St. Rank hold GSK as of Q2 2021.
- Cullinan Associates reported no remaining GSK position as of Q2 2021 after selling out during the quarter.
- Cullinan Associates sold 6,320 GSK shares in Q2 2021, an estimated $282K.
- Cullinan Associates first reported a position in GSK in Q3 2013 and held it in 29 quarters.
- Cullinan Associates's GSK position peaked at $2.04M in Q1 2014.
- 798 funds tracked by Wall St. Rank held GSK as of Q2 2021.
Based on Cullinan Associates's 13F filing for Q2 2021, filed 7 Jul 2021.